L26/O-165 Exposure to Granulocyte Macrophage Colony Stimulating Factor (GM-CSF) in frozen embryo transfers leads to improved pregnancy outcomes in autologous cycles: a retrospective cohort analysis
Human Reproduction · 01.07.2026 · 41 (Supplement_1)
DOI: 10.1093/humrep/deag083.163 ↗Kurz gefasst
Fachartikel in der Zeitschrift Human Reproduction, online erschienen am 08.07.2026. Verfasst von M.D.L.L. Medrano und 8 weiteren Autor:innen.
Abstract (Originalsprache)
Study question Does the use of medium containing GM-CSF for post-thaw embryo recovery and embryo transfer improve pregnancy outcomes across patient groups? Summary answer GM-CSF containing medium for post thaw embryo recovery and transfer is associated with improved biochemical and clinical pregnancy outcomes in cycles with autologous oocytes. What is known already GM-CSF is a cytokine naturally found in the endometrium, where it modulates the immunological embryo-endometrial interaction and facilitates endometrial receptivity and embryo implantation. Given its biological role, one could hypothesize that culturing vitrified-warmed embryos prior to transfer with GM-CSF, and transferring them with the same molecule, could improve implantation. Emerging evidence has suggested this possibility, with one study reporting increased biochemical, clinical and ongoing pregnancy and live birth rates. Nevertheless, GM-CSF contribution to reproductive outcomes across different patient populations has not been fully established yet. Study design, size, duration This retrospective cohort study evaluated 782 frozen embryo transfer (FET) cycles between December 2024-December 2025. Group 1 (G1, n = 498, of which Autologous: n = 228; Donor: n = 270) was cultured (2-4 hours post thaw) and transferred in SAGE 1-StepTM with GM-CSF medium (CooperSurgical). Group 2 (G2, n = 284, of which Autologous: n = 148; Donor: n = 136) was cultured (2-4 hours) in global®total® (CooperSurgical) or Continuous Single Culture Complete (CSCC, Fuji-Irvine) and transferred in either global®total®, CSCC, or EmbryoGlue®(Vitrolife). Participants/materials, setting, methods Embryos were grouped by quality, Q1: ≥3 and AA, Q2: ≥3 and AB, BA, or BB and Q3: ≥3 and CB, BC or CC. Analyses were stratified by oocyte source. Logistic regression models were adjusted for maternal age, preimplantation genetic testing (PGT), embryo quality, oocyte type (fresh or frozen) and transfer day. Biochemical pregnancy and clinical pregnancy rates were compared between Group 1 and Group 2 using adjusted odds rations with 95% confidence intervals. Main results and the role of chance Women in autologous oocyte cycles had comparable age (G1: 37.2±4.5, G2: 37.1±4.5), BMI (G1: 24.3±7.0, 24.1±6.1) and % of donor sperm (G1: 12.7%, G2: 15.5%). In these cycles, recovery and transfer in GM-CSF containing media was associated with higher clinical pregnancy (adjusted OR = 1.72, 95% CI: 1.11-2.66, p = 0.015). Biochemical pregnancy was comparable between groups (adjusted OR = 1.29, 95% CI: 0.81-2.06, p = 0.277) suggesting a positive effect of GM-CSF on pregnancy support. As expected, PGT tested embryos resulted in improved biochemical (OR = 1.76, p = 0.019) and clinical pregnancy (OR = 1.71, p = 0.021). Lower embryo quality was associated with decreased biochemical and clinical pregnancy (Biochemical Pregnancy: Q3 vs Q1 - OR = 0.30, p = 0.006; Clinical Pregnancy: Q3 vs Q1 - OR = 0.35, p = 0.009). In donor oocyte cycles (recipient age – G1: 43.0±4.5, G2: 42.9±4.5; recipient BMI – G1: 24.4±5.9, G2: 24.5±6.0; % donor sperm – G1: 16.7%, G2: 13.2%) clinical pregnancy OR was 0.94 (95% CI: 0.62-1.42, p = 0.754) and biochemical pregnancy OR was 0.85 (95% CI: 0.55-1.30, p = 0.443). PGT tested embryos showed improved biochemical outcomes in donor cycles, but to a lesser extent than autologous cycles (OR = 1.59, p = 0.045), and comparable outcomes in clinical pregnancy (OR = 1.18, p = 0.454). Limitations, reasons for caution This retrospective study may be impacted by unaccounted for confounders. Donor cycles were analyzed separately to avoid oocyte quality-related bias, although this may have led to an uneven distribution of repeated implantation failures and repeated pregnancy loss cases, more prevalent in autologous cycles. Further studies should include live birth outcomes. Wider implications of the findings Medium containing GM-CSF for post warming recovery and embryo transfer may enhance pregnancy outcomes in a broad autologous patient population. Specifically, GM-CSF effect may relate to the maintenance of pregnancy viability after implantation, as evidenced by the increased clinical pregnancy rate. Trial registration number No
Zitieren
APA
Medrano, M., Ramos, B., Moya, I., Desai, V., Luna, J., Vilella, I., Parrella, A., Vassena, R., & Gómez, J. (2026). L26/O-165 Exposure to Granulocyte Macrophage Colony Stimulating Factor (GM-CSF) in frozen embryo transfers leads to improved pregnancy outcomes in autologous cycles: a retrospective cohort analysis. Human Reproduction, 41(Supplement_1). https://doi.org/10.1093/humrep/deag083.163
Vancouver
Medrano M, Ramos B, Moya I, Desai V, Luna J, Vilella I, et al. L26/O-165 Exposure to Granulocyte Macrophage Colony Stimulating Factor (GM-CSF) in frozen embryo transfers leads to improved pregnancy outcomes in autologous cycles: a retrospective cohort analysis. Human Reproduction. 2026;41(Supplement_1). doi:10.1093/humrep/deag083.163
BibTeX
@article{Medrano2026,
author = {Medrano, M.D.L.L. and Ramos, B. and Moya, I. and Desai, V. and Luna, J. and Vilella, I. and Parrella, A. and Vassena, R. and Gómez, J.M.},
title = {L26/O-165 Exposure to Granulocyte Macrophage Colony Stimulating Factor (GM-CSF) in frozen embryo transfers leads to improved pregnancy outcomes in autologous cycles: a retrospective cohort analysis},
journal = {Human Reproduction},
year = {2026},
volume = {41},
number = {Supplement_1},
doi = {10.1093/humrep/deag083.163}
}
EUVIMED